Publications

Scholarly Journals--Published

  • Arthur K, Belliard J C, Hardin S B, Knecht K, Chen C S, & Montgomery S. (2012). Practices, Attitudes, and Beliefs Associated With Complementary and Alternative Medicine (CAM) Use Among Cancer Patients. Integrative Cancer Therapies, 11(3), 232-242. Introduction. The high prevalence of complementary and alternative medicine (CAM) use among cancer patients (40%-83%) receiving conventional treatment and the complex relationship between the psychosocial factors that may contribute to or result from CAM use requires further understanding. The authors conducted a descriptive mixed-methods pilot study to understand CAM practices, attitudes, and beliefs among cancer patients at the Loma Linda University Medical Center. Methods. This was the qualitative phase of the study, and no hypotheses were set. A total of 23 face-to-face interviews were conducted, and thematic coding was used to analyze 22 interview transcriptions. There were 14 CAM users (64%) and 8 nonusers (36%). Findings. The themes present among those who used CAM were the following: physicians viewed as one aspect of health care options, a holistic view on well-being, satisfaction with CAM use, and 3 key coping methods (confrontive, supportive, and optimistic) to confront cancer. Themes were not independent of each other. Two themes were present among nonusers; nonusers trusted their physician and were more likely to express evasive coping methods. Discussion. Perceptions and behavioral patterns are complex predictors of CAM use. A better understanding of CAM, medical pluralism, and the perceptions of patients would help health care providers deliver a better quality of care. The promotion of integrative care may help health care providers better identify medical pluralism and would shift focus to patient-centered care. (09/2012) (link)
  • Arthur K, Belliard JC, Hardin SB, et al. Practices, Attitudes, and Beliefs associated with Complementary and Alternative Medicine (CAM) use among Cancer Patients. Integr Cancer Ther.  Feb, 2012 (epub ahead of print) (02/2012)
  • Hardin SB. Cancer stories: an argument for narrative ethics. Update. 2012;23:1-4. (2012)
  • Dragnev KH, Hardin SB, Pipas JM, Davis TH, Rigas JR. A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors. Chemotherapy. 2010;56:135-141. (2010)
  • Hardin SB.  Potential Hazards of Necessary Collusion [letter].  J Clin Oncol.  2005;23:7242.    (2005)
  • Hardin SB, Yusufaly YA.  Difficult end-of-life treatment decisions:  do other factors trump advance directives?  Arch Intern Med.  2004;164:1531-1533.  erratum in:  Arch Intern Med.  2004;164:2124.   (Presented as an abstract at the annual meeting of the Society of General Internal Medicine.  May, 2000, Boston.) (05/2000)
  • Loo LK, Byrne JM, Hardin SB, Castro D, Fisher FP.  Reporting medical information:  does the lay press get it right?  Abstract.  J Gen Intern Med.  1998;13S1:60. (1998)
  • Witman AB, Park DM, Hardin SB.  How do patients want physicians to handle mistakes?  a survey of internal medicine patients in an academic setting.  Arch Intern Med.  1996;156:2565-2569.  (Presented as an abstract at the annual meeting of the Society of General Internal Medicine.  May, 1996, Boston.) (05/1996)
  • Hardin SB, Loo LK.  Offering advance directives [letter].  Ann Intern Med.  1993;118:573. (1993)
  • Hardin SB, Welch HG, Fisher ES.  Counseling hospitalized patients about advance directives:  a randomized trial.  Abstract.  Clin Res.  1993;41(2):577A. (1993)
  • Hardin SB, Welch HG, Fisher ES.  Should advance directives be obtained in the hospital?  A review of patient competence during hospitalizations prior to death.  Abstract. Clin Res  1991.  (Presented as an abstract at the annual meeting of the Society of General Internal Medicine.  May, 1992, Seattle.) (05/1992)

Book Review - Scholarly Journals--Published

  • Manuscript in preparation:  A dose-escalation trial of the combination of docetaxel, gemcitabine, and filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors.  (Present)